Iterum Expands ORLYNVAH™ Coverage to 25 Million Lives in the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy ITRM?
Source: Globenewswire
- Expanded Coverage: ORLYNVAH™ now reaches nearly 25% of insured lives in the U.S., with increasing integration into employer groups and payer formularies, which is expected to enhance market penetration significantly.
- Pharmacy Benefit Agreement: Iterum has signed a rebate agreement with a top Medicare Part D Pharmacy Benefit Manager, positioning ORLYNVAH™ for inclusion in their formularies starting Q1 2026, which will greatly improve product accessibility in the market.
- Increased Distribution Channels: ORLYNVAH™ is now stocked at additional distributors like Cencora, allowing physicians to procure the product through various channels, thereby enhancing market availability and procurement flexibility for doctors.
- Patent Expansion: The European Patent Office has indicated its intention to grant a patent covering a bilayer tablet of sulopenem etzadroxil and probenecid, projected to expire in December 2039, which strengthens Iterum's intellectual property protection in the anti-infective space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITRM
Wall Street analysts forecast ITRM stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.150
Low
2.00
Averages
5.50
High
9.00
Current: 0.150
Low
2.00
Averages
5.50
High
9.00
About ITRM
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
ITERUM THERAPEUTICS PLC: FDA Suggests Type C Meeting for Proposed Clinical Study of ORLYNVAH
- FDA Recommendation: The FDA has recommended a type C meeting for a proposed clinical investigation related to Orlyn NVH.
- Purpose of Meeting: The meeting aims to discuss the clinical development plan and address any questions regarding the proposed investigation.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
Iterum Expands ORLYNVAH™ Coverage to 25 Million Lives in the U.S.
- Expanded Coverage: ORLYNVAH™ now reaches nearly 25% of insured lives in the U.S., with increasing integration into employer groups and payer formularies, which is expected to enhance market penetration significantly.
- Pharmacy Benefit Agreement: Iterum has signed a rebate agreement with a top Medicare Part D Pharmacy Benefit Manager, positioning ORLYNVAH™ for inclusion in their formularies starting Q1 2026, which will greatly improve product accessibility in the market.
- Increased Distribution Channels: ORLYNVAH™ is now stocked at additional distributors like Cencora, allowing physicians to procure the product through various channels, thereby enhancing market availability and procurement flexibility for doctors.
- Patent Expansion: The European Patent Office has indicated its intention to grant a patent covering a bilayer tablet of sulopenem etzadroxil and probenecid, projected to expire in December 2039, which strengthens Iterum's intellectual property protection in the anti-infective space.
See More
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
ITERUM THERAPEUTICS PLC: FDA Suggests Type C Meeting for Proposed Clinical Study of ORLYNVAH
- FDA Recommendation: The FDA has recommended a type C meeting for a proposed clinical investigation related to Orlyn NVH.
- Purpose of Meeting: The meeting aims to discuss the clinical development plan and address any questions regarding the proposed investigation.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
Iterum Expands ORLYNVAH™ Coverage to 25 Million Lives in the U.S.
- Expanded Coverage: ORLYNVAH™ now reaches nearly 25% of insured lives in the U.S., with increasing integration into employer groups and payer formularies, which is expected to enhance market penetration significantly.
- Pharmacy Benefit Agreement: Iterum has signed a rebate agreement with a top Medicare Part D Pharmacy Benefit Manager, positioning ORLYNVAH™ for inclusion in their formularies starting Q1 2026, which will greatly improve product accessibility in the market.
- Increased Distribution Channels: ORLYNVAH™ is now stocked at additional distributors like Cencora, allowing physicians to procure the product through various channels, thereby enhancing market availability and procurement flexibility for doctors.
- Patent Expansion: The European Patent Office has indicated its intention to grant a patent covering a bilayer tablet of sulopenem etzadroxil and probenecid, projected to expire in December 2039, which strengthens Iterum's intellectual property protection in the anti-infective space.
See More
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
See More
